
INO — Inovio Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$1.33
+$0.06 (+4.72%)
Inovio Pharmaceuticals Inc (INO) is a biotechnology company listed on NASDAQ. It is led by Jacqueline E. Shea Ph.D., based in 660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462, with about 112 employees. Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Latest reported INO revenue for 2025-09-30 was $0. Net income was -$45.5M. INO currently screens at market cap $88.0M.
Use this INO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the INO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the INO SEC filings page. Lician reads the product cache first so this HTML stays unique to Inovio Pharmaceuticals Inc even when a live quote feed is slow.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
INO Key Statistics
Market Cap
$88.03M
Volume
3.60M
Previous Close
$1.25
Day Range
$1.24 – $1.30
EPS
-$3.95
Revenue
$217.76K
Net Income
-$107.25M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-73.8%
Profit Margin
-49254.3%
Employees
112
INO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $217.76K | $832.01K | $10.26M | $1.77M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$107.25M | -$135.12M | -$279.82M | -$303.66M |
| EPS (Diluted) | -$3.95 | -$6.09 | -$14.07 | -$17.45 |
Total Assets
$113.20M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$65.81M
Operating Cash Flow
-$104.08M
Free Cash Flow
$0.00
Inovio Pharmaceuticals Inc Company Information
- CEO, President & Director
- Jacqueline E. Shea Ph.D.
- Headquarters
- 660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462
- Website
- www.inovio.com
- Phone
- 267 440 4200
- IPO / Founded
- 1998-02-12
- Sector
- Healthcare
- Industry
- Biotechnology